CTIS2024-513102-57-00招募中1 期
A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of two formulations of vaginal micronized progesterone. - FSD-MIC-2022-03
Santiago Dexeus Font Fundacio Privada0 个研究点目标入组 1,020 人开始时间: 2024年4月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,020
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •patients undergoing an artificial cycle-frozen embryo transfer (AC-FET), Endometrial preparation with hormone replacement therapy, Age 18-43 years following an autologous IVF cycle (with or without preimplantation genetic testing for aneuploidy), Age < 50 years following an egg donation cycle, BMI > 18 and < 30 kg/m2, blastocyst embryo transfer, Willing to participate in the study, Able to come to the Center to comply with the procedures of the study: blood tests, appointments and drug dispensation.
排除标准
- •Uterine diseases (e.g. submucosal fibroids, polyps, previously diagnosed Müllerian abnormalities), Hydrosalpinx, Recurrent pregnancy loss (= 3 previous miscarriages), Recurrent implantation failure (= 3 previously failed embryo transfers of good-quality blastocysts), Allergy to study medication, pregnancy or lactation, Contraindication for hormonal treatment, Personalized initiation of exogenous progesterone according to a previous endometrial receptivity assay test, Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment).
研究者
相似试验
进行中（未招募）
1 期
A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance bacillus Calmette-Guerin therapy. - Hyperthermia plus mitomycin (HYMN)on muscle invasive bladder cancerMedDRA version: 9.1 Level: LLT Classification code 10005006 Term: Bladder cancer stage 0, with cancer in situMedDRA version: 9.1 Level: LLT Classification code 10005007 Term: Bladder cancer stage 0, without cancer in situMedDRA version: 9.1 Level: LLT Classification code 10005008 Term: Bladder cancer stage I, with cancer in situMedDRA version: 9.1 Level: LLT Classification code 10005009 Term: Bladder cancer stage I, without cancer in situEUCTR2008-005428-99-GBniversity College London104
招募中
3 期
A randomized controlled phase III study comparing docetaxel, cisplatin and 5-FU (2-weekly DCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer (JCOG1314, MIRACLE study)esophageal cancerJPRN-UMIN000015107Japan Clinical Oncology Group (JCOG)240
尚未招募
3 期
To Study effectiveness of oral chemotherapy with low dose immunotherapy compared with chemotherapy in Head and Neck Cancer PatientsCTRI/2024/01/061661Tata Memorial Centre
招募中
3 期
A Randomized, Phase III Controlled Study to Compare CAPOX Therapy as Post-operative Adjuvant Chemotherapy with Surgery Alone in Patients with Completely Resected Circulating Tumor DNA-negative High-risk Stage II and Low-risk Stage III Colon CancerColon CancerJPRN-jRCT1031200006Takemasa Ichiro1,000
已完成
3 期
Study to find out if restricting raw fruits in patients with blood cancer can reduce infections.CTRI/2018/01/011418Cancer Institute200